EUCTR2012-004301-27-IT进行中（未招募）1 期
A randomized, Phase III study of Fotemustine versus the Combination of Fotemustine and Ipilimumab in Patients with Metastatic Melanoma with brain metastasis - NIBIT-M2
FONDAZIONE NIBIT0 个研究点目标入组 160 人开始时间: 2012年10月30日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Signed Written Informed Consent
- •a) Willing and able to give written informed consent.
- •2) Target Population
- •a) Histologic diagnosis of malignant melanoma;
- •b) Stage IV melanoma;
- •c) No prior therapy for advanced (unresectable Stage III or Stage IV) disease;
- •d) No previous systemic corticosteroid therapy within 7 days; steroids for symptoms related to brain disease, developed during treatment are allowed;
- •e) Prior adjuvant treatment with IFN or other immunotherapy allowed with exception of anti-CTLA-4;
- •f) Presence of asymptomatic brain metastases: patients must have measurable metastases in the brain, defined as lesions that can be accurately measured in 2 dimensions as = 0.5 cm (maximum 2 cm) in the brain MRI with contrast;
- •g) Pts who have been previously treated with brain stereotactic radiotherapy (SRT), whole-brain radiotherapy (WBRT) and/or surgery, must have developed new measurable brain lesions;
- •h) Have a full set of baseline (i.e., Screening) digital images of cutaneous lesions and radiographic images, including, but not limited to: MRI of brain, CT of chest, abdomen, pelvis and soft tissue. All images must be of adequate quality as detailed in Section 6.4.1 of the protocol;
- •i) Life expectancy 12 weeks;
- •j) ECOG performance status of 0 or 1;
- •k) Required values for initial laboratory tests:
- •i) WBC >=3500/uL
- •ii) ANC >=2000/uL
- •iii) Platelets >=100 x 103/uL
- •iv) Hemoglobin >=9 g/dL
- •v) Creatinine <=2.5 x ULN
- •vi) AST <=2.5 x ULN for patients without liver metastasis
- •<= 5 x ULN for patients with liver metastasis
- •vii) Bilirubin <= 1.5 x ULN for patients without liver metastasis
- •<= 3 x ULN for patients with liver metastasis
- •< 3.0 mg/mL for patients with Gilbert’s Syndrome
- •Negative screening tests for HIV, Hepatitis B, and Hepatitis C. If positive results are not indicative of true active or chronic infection, the patient can enter the study after discussion and agreement between the Investigator and clinical monitor.
- •3) Age and Sex
- •a) Men and women, of and over 18 years old.
- •Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the study in such a manner that the risk of pregnancy is minimized.
- •WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal. Post menopause is defined as:
- •(1) Amenorrhea >=12 consecutive months without another cause or
- •(2) For women with irregular menstrual periods and on hormone replacement therapy (HRT), a documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Sex and Reproductive Status
- •a) WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the study;
- •b) Women who are pregnant or breastfeeding;
- •c) Women with a positive pregnancy test on enrollment or prior to investigational product administration;
- •d) Sexually active fertile men not using effective birth control if their partners are WOCBP.
- •2) Target Disease Exceptions
- •a) Any malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix;
- •b) Primary ocular or mucosal melanoma.
- •3) Medical History and Concurrent Diseases
- •a) Symptomatic brain metastases requiring immediate local intervention (radiotherapy (RT) and/or surgery);
- •b) Leptominingeal involvement by disease;
- •c) Autoimmune disease: Patients with a documented history of Inflammatory Bowel Disease, including ulcerative colitis and Crohn’s disease are excluded from this study as are patients with a documented history of symptomatic autoimmune disease (eg, rheumatoid arthritis, systemic progressive sclerosis [scleroderma], Systemic Lupus Erythematosus, autoimmune vasculitis [eg, Wegener’s Granulomatosis] and autoimmune hepatitis. Subjects with motor neuropathy considered of autoimmune origin (eg, Guillain-Barre Syndrom) are also excluded from this study;
- •d) Any underlying medical condition, which in the opinion of the investigator, will make the administration of study drug hazardous or obscure the interpretation of adverse events, such as a condition associated with frequent diarrhea.
- •4) Prohibited Treatments and/or Therapies
- •a) Concomitant therapy with any anti-cancer agent; immunosuppressive agents; any non-oncology vaccine therapy used for prevention of infectious diseases (for up to 1 month prior to or after any dose of study drug); surgery or radiotherapy (except as described in Sections 5.5.1 and 5.5.2); other investigational anti-cancer therapies; or chronic use of systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses);
- •b) Previous treatment with other investigational products, including cancer immunotherapy, within 30 days;
- •c) Prior treatment with anti-CTLA-4 and/or fotemustine.
- •5) Other Exclusion Criteria
- •a) Prisoners or subjects who are involuntarily incarcerated;
- •b) Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.
研究者
相似试验
Unknown
3 期
A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain MetastasisBrain MetastasesNCT02460068Italian Network for Tumor Biotherapy Foundation168
进行中（未招募）
不适用
Phase II multicenter study with Fotemustine and Temozolomide modulation in patients with metastatic melanoma (MM) - Phase II multicenter study with Fotemustine and Temozolomide in MMPatients with metastatic melanoma non pre-treated for advanced diseaseMedDRA version: 12.1Level: LLTClassification code 10027481Term: Metastatic melanomaEUCTR2009-016487-36-ITGOIM GRUPPO ONCOLOGICO MERIDIONALE
进行中（未招募）
不适用
Phase II trial evaluating fotemustine (Muphoran) treatment in patients with refractory or relapsing multiple myeloma - NDMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomamultiple myelomaEUCTR2008-001175-29-ITOSPEDALE POLICLINICO S. MATTEO
进行中（未招募）
1 期
A randomized study to comparelomustine with lomustine and bevacizumab for patients with recurrent malignant brain tumors.EUCTR2020-003545-11-DKRigshospitalet168
进行中（未招募）
不适用
Second line therapy with low dose fotemustine in progressive malignant gliomas - fotgmProgressive malignant gliomas patientsMedDRA version: 9.1Level: LLTClassification code 10006131Term: Brain neoplasm malignantEUCTR2008-003342-29-ITISTITUTI FISIOTERAPICI OSPITALIERI